Genmab: Epcoritamab video
-
Learn more about the proposed mechanism of action of epcoritamab (DuoBody-CD3xCD20).
Epcoritamab is a proprietary bispecific antibody created using Genmab's DuoBody
technology. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B-cell malignancies. Please note, Epcoritamab is an investigational compound and its safety and efficacy has not been established. For more information, please contact [email protected]
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind